CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced that Health Canada has approved ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine), with conditions, for the treatment of amyotrophic lateral sclerosis (ALS). Clinical data demonstrated a statistically significant and clinically meaningful benefit in functional outcomes for people with ALS taking ALBRIOZA (also known as AMX0035) compared to people taking placebo, either as a stand-alone therapy or when added to existing treatments for ALS. This decision marks the first marketing approval for ALBRIOZA issued to Amylyx worldwide.
For nearly a decade, we have been committed to creating more meaningful moments for people living with ALS and their families. We are excited with Health Canadas decision to approve ALBRIOZA with conditions. ALBRIOZA is a therapy that demonstrated in our CENTAUR trial a statistically significant and clinically meaningful impact on function, alone or in addition to existing ALS therapies. We are grateful to the people who participated in our clinical trials, their families, the researchers, and the ALS community for helping to make this milestone happen, said Justin Klee and Joshua Cohen, Co-CEOs and Co-Founders of Amylyx.
ALS is a relentlessly progressive and fatal neurodegenerative disorder caused by motor neuron death in the brain and spinal cord. Motor neuron loss in ALS leads to deteriorating muscle function, the inability to move and speak, respiratory paralysis, and eventually death. The vast majority of people with ALS (>90%) have sporadic disease, showing no clear family history. Approximately 3,000 Canadians are currently living with ALS, and the average life expectancy from symptom onset is two to five years. Approximately 1,000 people die from ALS in Canada every year, with a similar number of diagnoses annually.
I have always had a love for life and a passion for global advocacy. Thanks to new innovations in ALS treatment and care, Ive been able to continue my advocacy work in new ways as part of the fight for new treatment options for the ALS community, said Norman MacIsaac, who has been living with ALS since 2014. New therapies like ALBRIOZA are critical to help me and others have a fuller life. The ability to live more independently for longer is incredibly meaningful.
For more than 30 years, I have been involved with caring for people living with ALS, and we have had major breakthroughs in research and made strides in drug development. The approval of ALBRIOZA is a testament to this progress, said Angela Genge, MD, FRCP(C), Director of the ALS Global Centre for Excellence at the Montreal Neurological Institute. New treatment options that can slow disease progression are critical to give people living with ALS more time as we work toward a cure.
The approval of ALBRIOZA was authorized under Health Canada's Notice of Compliance with Conditions (NOC/c) policy. One of the conditions of the approval is the provision of data from the ongoing Phase 3 PHOENIX trial. Other conditions include additional planned or ongoing studies. Amylyx anticipates topline results from the PHOENIX trial in 2024.
The approval of ALBRIOZA is based on data from CENTAUR, a multicenter Phase 2 clinical trial in 137 participants with ALS encompassing a 6-month randomized placebo-controlled phase and an open-label long-term follow-up phase, which demonstrated that participants treated with ALBRIOZA scored, on average, 2.32 points higher on the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) over a period of 24 weeks. Detailed data from CENTAUR were published in the New England Journal of Medicine, Muscle & Nerve, and the Journal of Neurology, Neurosurgery, and Psychiatry.
We are delighted that this Health Canada approval represents the advancement in available treatment options for people living with ALS, but there is still more work to be done, said Tammy Moore, CEO of the ALS Society of Canada. ALS is a devastating disease and can move with startling swiftness. It is incredibly important that all Canadians across the country are able to benefit from these and other innovations to come, as quickly as possible following regulatory approval. We are hopeful that decision-makers throughout the drug access and reimbursement process will work expeditiously to provide timely and equitable access for all Canadians who may benefit. There is simply no time to wait with this disease.
The approval by Health Canada, the first for Amylyx globally, is an important milestone and first step, said Chris Aiello, General Manager and Head of Canada at Amylyx. We anticipate that ALBRIOZA will be available commercially in Canada within the next six weeks. We are prepared to work with the pan-Canadian Pharmaceutical Alliance (pCPA) and federal, provincial and territorial governments to negotiate the listing of ALBRIOZA expeditiously, so that eligible Canadians living with ALS can obtain access as quickly and efficiently as possible.
As part of Amylyx continued commitment to the ALS community, the Amylyx Care Team (ACT) Support Program provides insurance navigation, treatment coordination and educational support for people living with ALS who have been prescribed ALBRIOZA and their caregivers. Eligibility and enrolment into the ACT Support Program can be discussed with prescribing health care professionals.
Marketing Application Reviews & Clinical Update
AMX0035 has been granted Priority Review by the U.S. Food and Drug Administration (FDA) and assigned a Prescription Drug User Fee Act date of September 29, 2022. Additionally, The European Medicines Agency (EMA) has validated the submission of the Companys Marketing Authorisation Application for AMX0035 for the treatment of ALS in Europe and it is under review. A 48-week, randomized placebo-controlled Phase 3 PHOENIX (NCT05021536) trial of AMX0035 in more than 65 sites across the U.S. and Europe is underway.
About the CENTAUR Trial
CENTAUR was a multicenter Phase 2 clinical trial in 137 participants with ALS encompassing a 6-month randomized placebo-controlled phase and an open-label long-term follow-up phase. The trial met its primary efficacy endpoint of reducing functional decline as measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R).
Overall, reported rates of adverse events and discontinuations were similar between AMX0035 and placebo groups during the 24-week randomized phase; however, GI events occurred with greater frequency (2%) in the AMX0035 group. Detailed safety and functional efficacy data from CENTAUR were published in the New England Journal of Medicine. Data from additional analyses from the CENTAUR trial were published in Muscle & Nerve in 2020 and 2022, and the Journal of Neurology, Neurosurgery and Psychiatry in 2022.
The CENTAUR trial was funded, in part, by the ALS ACT grant and the ALS Ice Bucket Challenge, and was supported by The ALS Association, ALS Finding a Cure (a program of The Leandro P. Rizzuto Foundation), the Northeast ALS Consortium, and the Sean M. Healey & AMG Center for ALS at Mass General.
About ALBRIOZA
ALBRIOZA (sodium phenylbutyrate and taurursodiol) is an oral fixed-dose medication approved with conditions to treat amyotrophic lateral sclerosis (ALS) in Canada. The combination of sodium phenylbutyrate and taurursodiol may reduce neuronal cell death, hypothesized to occur by simultaneously mitigating endoplasmic reticulum (ER) stress and mitochondrial dysfunction. ALBRIOZA is being explored for the potential treatment of other neurodegenerative diseases.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA. For more information, visit amylyx.com and follow us on LinkedIn and Twitter. For investors please visit investors.amylyx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the potential approval of AMX0035 for the treatment of ALS in countries other than Canada; the potential of AMX0035 as a treatment for ALS; the potential market acceptance and market opportunity for ALBRIOZA; the Companys ability to conduct a confirmatory trial of AMX0035 as a treatment for ALS; the Companys ability to make ALBRIOZA available commercially in Canada, as well as access to and coverage for ALBRIOZA; and expectations regarding our longer-term strategy. Any forward-looking statements in this statement are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Amylyx program development activities, Amylyx ability to successfully launch ALBRIOZA in Canada, Amylyx ability to execute on its commercial and regulatory strategy, regulatory developments, expectations regarding the timing of FDA and EMA review of AMX0035 for the treatment of ALS, Amylyx ability to fund operations, and the impact that the ongoing COVID-19 pandemic will have on Amylyx operations, as well as the risks and uncertainties set forth in Amylyx United States Securities and Exchange Commission (SEC) filings, including Amylyx Annual Report on Form 10-K for the year ended December 31, 2021, and subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220531006018/en/
Go here to read the rest:
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA ...
- Jake Diekman throws BP session for Rangers | MLB.com - MLB.com [Last Updated On: August 6th, 2017] [Originally Added On: August 6th, 2017]
- Cerebral palsy: Symptoms, diagnosis, treatment [Last Updated On: December 5th, 2017] [Originally Added On: December 5th, 2017]
- Hypothalamus - the body's thermostat | ASU - Ask A Biologist [Last Updated On: December 6th, 2017] [Originally Added On: December 6th, 2017]
- When Stroke Affects the Thalamus - Stroke Connection ... [Last Updated On: December 28th, 2017] [Originally Added On: December 28th, 2017]
- The Endocrine System: Hypothalamus and Pituitary [Last Updated On: December 28th, 2017] [Originally Added On: December 28th, 2017]
- Hypothalamus - Anatomy, Blood supply and Function | Kenhub [Last Updated On: December 28th, 2017] [Originally Added On: December 28th, 2017]
- Ulcerative Colitis - Cedars-Sinai [Last Updated On: January 6th, 2018] [Originally Added On: January 6th, 2018]
- Ulcerative colitis - Treatment - NHS.UK [Last Updated On: January 7th, 2018] [Originally Added On: January 7th, 2018]
- Business Directory | Uptown Waterloo Business Improvement Area [Last Updated On: January 8th, 2018] [Originally Added On: January 8th, 2018]
- Will States Continue To Fund Stem Cell Research? : Shots ... [Last Updated On: January 28th, 2018] [Originally Added On: January 28th, 2018]
- Spinal Cord Injuries - emedicine.medscape.com [Last Updated On: February 15th, 2018] [Originally Added On: February 15th, 2018]
- Spinal Cord Injuries - spine.org [Last Updated On: February 15th, 2018] [Originally Added On: February 15th, 2018]
- Journal of Clinical & Experimental Cardiology - Open Access Journals [Last Updated On: April 10th, 2018] [Originally Added On: April 10th, 2018]
- Cardiology Treatment - Fortis Healthcare [Last Updated On: April 10th, 2018] [Originally Added On: April 10th, 2018]
- Biology Junction [Last Updated On: April 12th, 2018] [Originally Added On: April 12th, 2018]
- Managing Right Ventricular Failure in PAH: An Algorithmic ... [Last Updated On: April 14th, 2018] [Originally Added On: April 14th, 2018]
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in ... [Last Updated On: April 22nd, 2018] [Originally Added On: April 22nd, 2018]
- Cardiovascular Pharmacotherapeutics: William H. Frishman ... [Last Updated On: May 13th, 2018] [Originally Added On: May 13th, 2018]
- 13 Super Foods Good for Eczema - Top Eczema Treatments [Last Updated On: May 15th, 2018] [Originally Added On: May 15th, 2018]
- Diagnosis & Treatment of Parkinson's - ParkinsonsDisease.net [Last Updated On: May 30th, 2018] [Originally Added On: May 30th, 2018]
- Arizona Heart Rhythm Center [Last Updated On: June 10th, 2018] [Originally Added On: June 10th, 2018]
- Ayurvedic Medicines for Ulcerative Colitis | Natural ... [Last Updated On: June 21st, 2018] [Originally Added On: June 21st, 2018]
- Weinstein Cardiovascular Development and Regeneration Meeting [Last Updated On: June 30th, 2018] [Originally Added On: June 30th, 2018]
- Ulcerative Colitis Information Centre [Last Updated On: July 31st, 2018] [Originally Added On: July 31st, 2018]
- Sudden Death in Dogs - Pet Health Network | Pet Health ... [Last Updated On: August 7th, 2018] [Originally Added On: August 7th, 2018]
- Coronary Heart Disease - Ischaemic heart disease - British ... [Last Updated On: August 21st, 2018] [Originally Added On: August 21st, 2018]
- Cardiac Rehabilitation: Overview, History and Definition ... [Last Updated On: August 25th, 2018] [Originally Added On: August 25th, 2018]
- Difference between Cardiac Arrest and Respiratory Arrest ... [Last Updated On: August 25th, 2018] [Originally Added On: August 25th, 2018]
- ECM for Pericardial Closure - Aziyo [Last Updated On: August 25th, 2018] [Originally Added On: August 25th, 2018]
- Adult Mental Health | Georgia Department of Behavioral Health ... [Last Updated On: September 6th, 2018] [Originally Added On: September 6th, 2018]
- Mental Health | ECLKC [Last Updated On: September 6th, 2018] [Originally Added On: September 6th, 2018]
- Mental Health - The Church of Jesus Christ of Latter-day Saints [Last Updated On: September 6th, 2018] [Originally Added On: September 6th, 2018]
- Center for Vascular Biology - Home | UConn Health [Last Updated On: September 22nd, 2018] [Originally Added On: September 22nd, 2018]
- # Diabetes Stem Cell Research Diabetes Care Measures [Last Updated On: September 30th, 2018] [Originally Added On: September 30th, 2018]
- Cardiac Rhythm Disturbances | The Patient Guide to Heart ... [Last Updated On: November 2nd, 2018] [Originally Added On: November 2nd, 2018]
- Arrhythmia | Cleveland Clinic [Last Updated On: November 2nd, 2018] [Originally Added On: November 2nd, 2018]
- Hyperbaric Oxygen Therapy for Wound Healing | Johns ... [Last Updated On: November 13th, 2018] [Originally Added On: November 13th, 2018]
- NIMH Home [Last Updated On: November 24th, 2018] [Originally Added On: November 24th, 2018]
- What is an interventional cardiologist? | Heart Surgeries ... [Last Updated On: November 26th, 2018] [Originally Added On: November 26th, 2018]
- Molecular Cardiology Research Institute Boston | Tufts ... [Last Updated On: November 29th, 2018] [Originally Added On: November 29th, 2018]
- Lower vascular plant | botany | Britannica.com [Last Updated On: December 7th, 2018] [Originally Added On: December 7th, 2018]
- Welcome to the ABG Tutorial Welcome to Hansen [Last Updated On: December 12th, 2018] [Originally Added On: December 12th, 2018]
- Cardiac catheterization - Wikipedia [Last Updated On: December 12th, 2018] [Originally Added On: December 12th, 2018]
- Stem Cell Research & Therapy | Home page [Last Updated On: December 22nd, 2018] [Originally Added On: December 22nd, 2018]
- Journal of Stem Cell Research and Therapy- Open Access ... [Last Updated On: December 22nd, 2018] [Originally Added On: December 22nd, 2018]
- Stem-cell therapy - Wikipedia [Last Updated On: December 22nd, 2018] [Originally Added On: December 22nd, 2018]
- Cardiology and Interventional Cardiology [Last Updated On: December 23rd, 2018] [Originally Added On: December 23rd, 2018]
- Rhode Island Interventional Cardiology | Cardiovascular ... [Last Updated On: December 23rd, 2018] [Originally Added On: December 23rd, 2018]
- Interventional Cardiology Certification Policies | ABIM.org [Last Updated On: December 23rd, 2018] [Originally Added On: December 23rd, 2018]
- Interventional Cardiology - Boston Scientific [Last Updated On: December 23rd, 2018] [Originally Added On: December 23rd, 2018]
- 9 Benefits of Human Growth Hormone (Along with Side ... [Last Updated On: December 27th, 2018] [Originally Added On: December 27th, 2018]
- Growth hormone deficiency - Wikipedia [Last Updated On: December 27th, 2018] [Originally Added On: December 27th, 2018]
- Dr. Lorrie Kirshenbaum, Cardiac Gene Biology | St ... [Last Updated On: January 28th, 2019] [Originally Added On: January 28th, 2019]
- Cardiomyopathy - CardioSmart [Last Updated On: February 8th, 2019] [Originally Added On: February 8th, 2019]
- Centenary Institute | Medical Research, Life Saving Research [Last Updated On: February 24th, 2019] [Originally Added On: February 24th, 2019]
- Cardiovascular Medicine | Department of Medicine [Last Updated On: March 29th, 2019] [Originally Added On: March 29th, 2019]
- Rapid Test Market 2019 with Recent Trends, Revenue, Demand and Top Manufactures- Bureau Veritas, SGS SA, Intertek Group plc, Eurofins Scientific -... [Last Updated On: October 11th, 2019] [Originally Added On: October 11th, 2019]
- Medical Imaging Equipment Market Research Report 2019: Global Industry Analysis, Business Development, Size, Share, Trends, Future Growth, Forecast To... [Last Updated On: October 11th, 2019] [Originally Added On: October 11th, 2019]
- Analysis on the Global DNA Read, Write & Edit Market, 2017-2019 and Forecast to 2024 - Yahoo Finance [Last Updated On: October 11th, 2019] [Originally Added On: October 11th, 2019]
- Cardiac Surgery Instruments Market is Expected to Tread a Steady Growth Trajectory by Clocking a CAGR of 5.9% from 2017 to 2022 - Health News Office [Last Updated On: October 24th, 2019] [Originally Added On: October 24th, 2019]
- PEDIATRIC MEDICAL DEVICES MARKET IS PROJECTED TO EXPAND AT A CAGR OF 8.0% FROM 2018 TO 2026 - Health News Office [Last Updated On: November 1st, 2019] [Originally Added On: November 1st, 2019]
- myTAIHEART Test Provides Evidence for Injury from Biopsy of Heart Transplant Recipients Cardiology2.0 - Cardiology2.0 [Last Updated On: November 1st, 2019] [Originally Added On: November 1st, 2019]
- Mental health and your heart - British Heart Foundation [Last Updated On: November 19th, 2019] [Originally Added On: November 19th, 2019]
- BUZZ-U.S. STOCKS ON THE MOVE-Cango, Gulfport Energy, Abiomed, Standard Diversified, Wanda Sports, Eidos - Nasdaq [Last Updated On: November 19th, 2019] [Originally Added On: November 19th, 2019]
- Cost Analysis of COPD Exacerbations and Cardiovascular Events in SUMMIT - AJMC.com Managed Markets Network [Last Updated On: November 19th, 2019] [Originally Added On: November 19th, 2019]
- Hundreds walk to defeat ALS in Ancient City - St. Augustine Record [Last Updated On: November 22nd, 2019] [Originally Added On: November 22nd, 2019]
- Living with Lung Cancer: The Silver Linings - Curetoday.com [Last Updated On: November 22nd, 2019] [Originally Added On: November 22nd, 2019]
- Building the human spinal cord atlas - SynBioBeta [Last Updated On: November 22nd, 2019] [Originally Added On: November 22nd, 2019]
- The Week That Wasn't: Keto and the Flu, Human Cyborg, Duvet Disease - Medscape [Last Updated On: November 22nd, 2019] [Originally Added On: November 22nd, 2019]
- ALS advance offers hope for those diagnosed with deadly disease - WRAL.com [Last Updated On: November 22nd, 2019] [Originally Added On: November 22nd, 2019]
- ALS Stem Cell Therapy Developer Seeks Amendment to its AstroRx Trial - ALS News Today [Last Updated On: November 22nd, 2019] [Originally Added On: November 22nd, 2019]
- Former Boston Globe writer, current NHL executive Snow diagnosed with ALS | College Hockey - USCHO [Last Updated On: December 23rd, 2019] [Originally Added On: December 23rd, 2019]
- AB Science announces the publication of new results in the peer-reviewed journal Glia that further support masitinib's potential mode of action in ALS... [Last Updated On: December 23rd, 2019] [Originally Added On: December 23rd, 2019]
- Christmas in the City thrills homeless families, takes on poignancy with founders ALS diagnosis - The Boston Globe [Last Updated On: December 23rd, 2019] [Originally Added On: December 23rd, 2019]
- Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial - Business... [Last Updated On: December 23rd, 2019] [Originally Added On: December 23rd, 2019]
- RADICAVA (edaravone) [Last Updated On: December 23rd, 2019] [Originally Added On: December 23rd, 2019]
- List of Amyotrophic Lateral Sclerosis Medications (5 Compared ... [Last Updated On: December 23rd, 2019] [Originally Added On: December 23rd, 2019]
- Neuropore Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson's Disease and... [Last Updated On: January 14th, 2020] [Originally Added On: January 14th, 2020]
- Comprehensive Analysis on Prostacyclin Market based on types and application - Technology Magazine [Last Updated On: January 18th, 2020] [Originally Added On: January 18th, 2020]
- N.J. karate legend who inspired thousands loses battle with ALS - NJ.com [Last Updated On: January 18th, 2020] [Originally Added On: January 18th, 2020]